Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445407 | 0.80 | MAPK1 (0.44) | MAPK1TSHRPOLBGPR35PIN1 | |
| SCHEMBL113455 | 0.80 | MAPK1 (0.44) | MAPK1TSHRPOLBGPR35PIN1 | |
| SCHEMBL202290 | 0.80 | ERN1 (0.41) | ERN1MEN1POLBPKMKMT2A | |
| SCHEMBL29600703 | 0.80 | ERN1 (0.41) | ERN1MEN1POLBPKMKMT2A | |
| SCHEMBL6512051 | 0.80 | ERN1 (0.41) | ERN1MEN1POLBPKMKMT2A | |
| SCHEMBL5033872 | 0.80 | MAPT (0.42) | MAPK1MEN1POLBKMT2AEGFR | |
| SCHEMBL29780392 | 0.78 | AHR (0.51) | MAPK1TSHRMEN1PKMKMT2A | |
| SCHEMBL985995 | 0.78 | AHR (0.51) | MAPK1TSHRMEN1PKMKMT2A | |
| SCHEMBL27732124 | 0.78 | KMT2A (0.41) | ERN1MEN1POLBPKMKMT2A | |
| SCHEMBL18224443 | 0.77 | ATM (0.31) | ERN1EGFRS100A4TRPV1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120887867-B | Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof | 浙江中医药大学 | 2026-05-15 | — | — | CN | claimed |
| CN-112441970-A | 2, 5-disubstituted-3-aminopyridine compound and preparation method and application thereof | 天津医科大学 | 2021-03-05 | — | — | CN | claimed |
| CN-102372707-A | Synthetic method of 6-methyl-4-bromine-1,6-dihydropyrrole[2,3-c]pyridine-7-one | WUXI APPTEC CO LTD | 2012-03-14 | — | — | CN | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-120887867-B | Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof | 浙江中医药大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12527737-B2 | Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE LTD (SG) | 2025-12-25 | — | — | US | disclosed |
| EP-0107914-B1 | AMINOPYRIMIDINONE DERIVATIVES USEFUL AS HISTAMINE H1-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
| US-4537891-A | 2-(3,5-Substituted-2-pyridylalkylamino)-5-benzyl-4-pyrimidones | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-08-27 | — | — | US | disclosed |
| US-4537890-A | 2-(3,5-Substituted-2-pyridylalkylamino)-5-oxopyridylmethyl-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-08-27 | — | — | US | disclosed |
| US-4532252-A | 3,5-Substituted-2-pyridylalkylamino compounds having histamine H1 -antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-07-30 | — | — | US | disclosed |
| EP-0134091-A1 | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-03-13 | — | — | EP | disclosed |
| EP-0122109-A2 | Preparation of cyano- or aminoalkyl substituted aromatic amines | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-10-17 | — | — | EP | disclosed |
| EP-0115132-A1 | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-08-08 | — | — | EP | disclosed |
| EP-0112142-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0107914-A1 | Aminopyrimidinone derivatives useful as histamine H1-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | ERN1 4118/4885MAPK1 2218/4885TSHR 3597/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | ERN1 2320/4885MAPK1 715/4885TSHR 2846/4885 |
| US-12527737-B2 | Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors | TPM3, TPM4, MATK | ERN1 2625/4885MAPK1 526/4885TSHR 570/4885 |
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | PKMYT1, PKN1, PRKCB | ERN1 417/4885MAPK1 267/4885TSHR 548/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | ERN1 757/4885MAPK1 614/4885TSHR 328/4885 |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CBR3, CYCS, CBR1 | ERN1 2053/4885MAPK1 3819/4885TSHR 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.